ArticleBMC ophthalmology2025
Photodynamic treatment without verteporfin in chronic central serous chorioretinopathy.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to evaluate the clinical and optical coherence tomography (OCT) results of a newly proposed technique to treat chronic central serous chorioretinopathy (cCSR) and to determine its efficacy in cCSR treatment. This technique is termed photostatic treatment (PST). STUDY
designA prospective study which includes 44 eyes of 38 patients were treated with PST and followed up for at least 24 months.
methodsPST was performed by administering light energy delivered to the area using a 689 nm diode laser. PST was performed using the conventional fluence rate (60 J/cm
resultsThe median central macular thickness (CMT) was significantly lower at the final visit after treatment than the initial presentation (median CMT 332,5µ versus 234µ, p < 0.001). Complete resolution of the fluid at the last visit could be achieved in 31 (70.4%) eyes with a significant improvement in median BCVA (p < 0.001).
conclusionThe application of laser treatment without a photosensitizing agent proved effective in controlling cCSR, and we propose the term 'photostatic treatment' for this new technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.